Figure 7 displays a forest plot for the network meta-analysis of studies reporting ACR50 response rates. Two comparisons were used in this analysis. Study-level data used in this Figure are presented in Appendix C. This figure is described further in the KQ1 Results section “Non-TNF Biologic: MTX Plus Non-TNF With Either MTX or Non-TNF Biologic” as follows: “NWMA favored the combination of MTX plus TCZ over TCZ monotherapy for ACR50 response but was not statistically significant (RR, 1.08; 95% CI, 0.96 to 1.21)… Similarly, the combination of MTX plus ABA was favored over ABA for ACR50 response, but the difference was not statistically significant (RR, 1.18; 95% CI, 0.95 to 1.47)”.

Figure 7Forest plot for network meta-analysis of ACR50 response rates: MTX plus non-TNF versus non-TNF biologic

95% CI = 95% confidence interval; ACR50 = American College of Rheumatology 50% improvement; MTX = methotrexate; RR = relative risk; TNF = tumor necrosis factor; vs. = versus.

From: Results

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.